Skip to main content

Table 5 Biomarkers and adipokines

From: A 2-year follow-up to a randomized controlled trial on resistance training in postmenopausal women: vasomotor symptoms, quality of life and cardiovascular risk markers

Variables

IG (n = 18)

CG (n = 17)

Type III fixed effectsa

Biomarkers & adipokines§,b

BL

n = 18

24-28 m

n = 18

BL

n = 17

24-28 m

n = 15

Group

F(p-value)

Time

F(p-value)

Group x Time

F(p-value)

Leptin (ng/mL)

31.5 (18.1/61.1)

36.9 (21.8/55.1)

41.4 (16.5/62.7)

33.5 (18.4/66.4)

0.176

(0.677)

0.582

(0.564)

0.536

(0.590)

MMP2 (ng/mL)

143.7 (126.3/158.8)

138.9 (114.0/149.3)

129.4 (114.5/166.2)

140.6 (119.7/156.9)

0.070

(0.794)

0.583

(0.563)

1.169

(0.320)

MMP9 (ng/mL)

35.7 (24.9/50.0)

32.8 (27.6/41.3)

41.1 (34.4/60.0)

35.9 (27.7/48.3)

1.392

(0.246)

4.595

(0.016*)

0.469

(0.629)

Adipsin (μg/mL)

5.9 (5.3/6.8)

6.4 (5.8/7.3)

6.7 (5.4/7.7)

6.1 (5.4/7.0)

0.195

(0.663)

0.229

(0.797)

0.870

(0.432)

Adiponectin (μg/mL)

33.2 (27.9/60.7)

35.7 (22.6/60.5)

47.2 (28.4/90.4)

50.4 (26.7/76.9)

2.404

(0.130)

1.492

(0.241)

1.885

(0.169)

Lipocalin 2 (μg/mL)

91.1 (75.2/103.2)

102.9 (83.6/115.0)

124.4 (101.8/140.9)

89.8 (71.0/109.7)

1.391

(0.245)

0.417

(0.661)

5.410

(0.008**)

PAI1 (ng/mL)c

20.9 (18.8/43.9)

29.3 (20.6/41.2)

35.4 (28.1/54.1)

39.3 (25.8/59.5)

3.434

(0.073)

0.402

(0.672)

0.613

(0.548)

Resistin (ng/mL)

24.3 (20.4/26.9)

23.9 (18.3/28.6)

24.2 (20.2/34.2)

22.5 (17.4/31.3)

0.543

(0.465)

0.700

(0.504)

1.987

(0.154)

MCP1 (pg/mL)

254.4 (203.8/417.9)

270.2 (224.2/374.1)

289.4 (250.8/446.7)

319.0 (275.5/348.5)

1.786

(0.190)

1.042

(0.365)

0.405

(0.670)

TNFα (pg/mL)

26.0 (13.6/42.2)

25.5 (22.0/43.2)

42.7 (29.6/57.4)

41.7 (34.5/54.3)

2.853

(0.100)

0.353

(0.705)

0.059

(0.943)

IL1-RA (pg/ml

254.6 (74.1/505.7)

221.9 (112.6/473.4)

316.4 (243.4/469.8)

344.6 (272.2/505.5)

5.479

(0.025*)

0.509

(0.606)

1.527

(0.231)

IL-10 (pg/mL)

6.1 (4.8/7.3)

5.5 (3.5/7.3)

6.0 (4.9/8.4)

5.6 (4.9/7.8)

0.398

(0.532)

1.049

(0.361)

1.803

(0.179)

IL-6 (pg/mL)c

0.8 (0.5/1.1)

0.8 (0.4/1.2)

0.8 (0.7/1.4)

0.7 (0.4/1.4)

0.087

(0.770)

0.959

(0.396)

0.226

(0.799)

BDNF (ng/mL)c

2.5 (0.6/6.9)¤

1.9 (1.0/3.9)

2.1 (0.4/5.9)

3.0 (1.2/6.4)

0.270

(0.607)

1.135

(0.334)

1.126

(0.336)

  1. IG Intervention group (i.e., performing a structured resistance training intervention), CG Control group (i.e., receiving a less structured introduction to resistance training after the initial 15 weeks of unchanged low physical activity), BL Baseline, 6 m Six months, 24-28 m the period within the additional follow-up visit was set post-intervention/control period to enable more participants to participate. Fourteen analytes were within detectable limits, including: adiponectin, adipsin, brain-derived neurotrophic factor (BDNF), interleukin-1 receptor antagonist (IL1-RA), interleukin 6 (IL-6), interleukin 10 (IL-10), leptin, lipocalin-2, matrix metalloproteinase 2 (MMP2), matrix metalloproteinase 9 (MMP9), monocyte chemoattractant protein 1 (MCP1), plasminogen activator inhibitor 1 (PAI-1), resistin, and tumor necrosis factor α (TNF-α)
  2. §Median (25th and 75th percentile); * p < 0.05; ** p < .001; ¤n = 17; ¤¤n = 16
  3. aLinear Mixed Models (LMMs)
  4. bLogaritmized values in the statistical analyses
  5. c + 10 was added as a constant before logaritmization to avoid negative values. The table mean/median values are the true values without the constant
Back to article page

BMC Women's Health

ISSN: 1472-6874

Contact us